SNY : Summary for Sanofi American Depositary Shar - Yahoo Finance

U.S. Markets close in 2 hrs 50 mins

Sanofi (SNY)


NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
44.72+0.05 (+0.10%)
As of 1:10PM EDT. Market open.
People also watch
NVSGSKAZNLLYNVO
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close44.67
Open44.69
Bid0.00 x
Ask0.00 x
Day's Range44.67 - 45.13
52 Week Range36.81 - 45.13
Volume612,082
Avg. Volume1,699,471
Market Cap110.51B
Beta0.76
PE Ratio (TTM)23.11
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.58 (3.56%)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • American City Business Journals1 hour ago

    Flexion tops $800M in market cap on Sanofi buyout rumor

    Shares of Burlington biotech Flexion Therapeutics soared to their highest point in more than a year and a half on Thursday following an unconfirmed report that French drug giant Sanofi is in talks to acquire the company for more than $1 billion. FiercePharma, citing an unnamed source, reported Thursday morning that the board of Flexion (FLXN) has voted to accept a non-binding offer from Sanofi (SNY), the parent company of Cambridge-based Sanofi-Genzyme. A Flexion spokesman declined comment, adding that the biotech will continue to pursue an “independent” strategy with its lead product, Zilretta, a long-acting steroid injection for osteoarthritis of the knee that could compete with one of Sanofi’s own treatments, Synvisc.

  • TheStreet.com2 hours ago

    Sanofi Said to Be Near $1 Billion Deal for Flexion

    Flexion is an arthritis-focused biotech company.

  • Reuters6 hours ago

    Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency

    Three of Europe's top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi and Roche likely to win approvals for two new products, while GlaxoSmithKline braces for a potential generic rival. Given earlier impressive clinical trial results, investors expect the Food and Drug Administration (FDA) to clear both Roche's multiple sclerosis (MS) treatment Ocrevus and Sanofi's new eczema drug Dupixent.